Dr. Rachel B. Salit
Claim this profileFred Hutch/University of Washington Cancer Consortium
Area of expertise
Myelofibrosis
Rachel B. Salit has run 3 trials for Myelofibrosis. Some of their research focus areas include:
Primary Myelofibrosis
Rachel B. Salit has run 3 trials for Primary Myelofibrosis. Some of their research focus areas include:
Affiliated Hospitals
Fred Hutch/University Of Washington Cancer Consortium
Clinical Trials Rachel B. Salit is currently running
Peritransplant Ruxolitinib
for Myelofibrosis
This phase II trial studies how well administering ruxolitinib before, during, and after allogeneic hematopoietic stem cell transplantation works in preventing graft versus host disease and improving transplant outcomes in patients with primary and secondary myelofibrosis. Donor hematopoietic stem cell transplantation (HSCT) is currently the only treatment with proven curative potential for myelofibrosis, however, myelofibrosis patients have a high risk for developing graft versus host disease post-transplant. Graft versus host disease is a condition where the transplanted cells from a donor can attack the body's normal cells. Ruxolitinib, a janus-associated kinase (JAK) inhibitor, is known to decrease inflammatory signals, which may reduce spleen size and decrease symptoms such as night sweats and weight loss. Administering ruxolitinib before, during, and after transplant may decrease the incidence and severity of graft versus host disease, increase survival, and improve quality of life in patients with primary and secondary myelofibrosis.
Recruiting
1 award
Phase 2
Stem Cell Transplant
for Myelofibrosis
This initial cohort of this phase II trial studied the outcomes of using a JAK inhibitor prior to reduced intensity haploidentical (Haplo) transplantation for the treatment of primary or secondary myelofibrosis (MF). The primary risk of using Haplo HCT in patients with MF is graft failure. In the first cohort, all patients engrafted. There were no instances of graft failure. However, a large number of patients did have graft versus host disease as a complication of their transplant. JAK inhibitors have since been approved for the indication of graft versus host disease treatment. And we are also using them for graft versus host disease prevention in a study of MF patients with sibling and unrelated donors. Therefore, we are opening a new cohort of the current study using the JAK inhibitor prior to, during and after Haplo transplant. Our goal is to decrease graft versus host disease in patients receiving a Haplo MF transplant without increasing the risk of graft failure.
Recruiting
1 award
Phase 2
More about Rachel B. Salit
Clinical Trial Related
11 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Rachel B. Salit has experience with
- Ruxolitinib
- Cyclophosphamide
- Fludarabine
- Tacrolimus
- Allogeneic Hematopoietic Stem Cell Transplantation
- JAK Inhibitor
Breakdown of trials Rachel B. Salit has run
Myelofibrosis
Primary Myelofibrosis
Follicular Lymphoma
Central Nervous System Hodgkin Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Rachel B. Salit specialize in?
Rachel B. Salit focuses on Myelofibrosis and Primary Myelofibrosis. In particular, much of their work with Myelofibrosis has involved HLA positive patients, or patients who are RB1 positive.
Is Rachel B. Salit currently recruiting for clinical trials?
Yes, Rachel B. Salit is currently recruiting for 2 clinical trials in Seattle Washington. If you're interested in participating, you should apply.
Are there any treatments that Rachel B. Salit has studied deeply?
Yes, Rachel B. Salit has studied treatments such as Ruxolitinib, Cyclophosphamide, Fludarabine.
What is the best way to schedule an appointment with Rachel B. Salit?
Apply for one of the trials that Rachel B. Salit is conducting.
What is the office address of Rachel B. Salit?
The office of Rachel B. Salit is located at: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington 98109 United States. This is the address for their practice at the Fred Hutch/University of Washington Cancer Consortium.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.